Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

ABT-761 (Abbott).

J J Reid1

  • 1Primary Care Faculty of Medicine, Dunedin School of Medicine, University of Otago, New Zealand. jim.reid@stonebow.otago.ac.nz

Current Opinion in Investigational Drugs (London, England : 2000)
|August 31, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

A method for the production of antiserum specific for Lancefield group D streptococci.

Journal of bacteriology·2010
Same author

The effect of 4-week streptozotocin-induced diabetes on responses to endothelin-1 in rat isolated atria.

Neurochemistry international·2010
Same author

The influence of mechanical handling upon the growth of single bacterial cell isolates.

Journal of bacteriology·2010
Same author

Mahmudi order and clan, 1500-1606.

The journal of Kurdish studies·2009
Same author

Reduced EDHF responses and connexin activity in mesenteric arteries from the insulin-resistant obese Zucker rat.

Diabetologia·2008
Same author

Impaired nitric oxide function in the basilar artery of the obese Zucker rat.

Journal of cardiovascular pharmacology·2003
Same journal

Reporting disease control rates or clinical benefit rates in early clinical trials of anticancer agents: useful endpoint or hype?

Current opinion in investigational drugs (London, England : 2000)·2011
Same journal

Abating progressive tissue injury and preserving function after CNS trauma: The role of inflammation modulatory therapies.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Teriflunomide, an inhibitor of dihydroorotate dehydrogenase for the potential oral treatment of multiple sclerosis.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Tralokinumab, an anti-IL-13 mAb for the potential treatment of asthma and COPD.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Vedolizumab, a humanized mAb against the α4β7 integrin for the potential treatment of ulcerative colitis and Crohn's disease.

Current opinion in investigational drugs (London, England : 2000)·2010
Same journal

Pitrakinra, a dual IL-4/IL-13 antagonist for the potential treatment of asthma and eczema.

Current opinion in investigational drugs (London, England : 2000)·2010
See all related articles

Abbott

Area of Science:

  • Pharmacology
  • Respiratory Medicine

Background:

  • ABT-761 is a novel 5-lipoxygenase inhibitor developed by Abbott.
  • It represents a follow-up compound to zileuton, aiming for improved efficacy and dosing convenience.

Purpose of the Study:

  • To evaluate the pharmacological profile and clinical efficacy of ABT-761 in asthma treatment.

Main Methods:

  • Preclinical assessment of potency and duration of action compared to existing inhibitors.
  • Phase III clinical trials in asthma patients.
  • Pharmacokinetic studies in healthy volunteers and children.

Main Results:

  • ABT-761 demonstrates significantly higher potency than Bay-X-1005 and zileuton.
  • It offers a longer duration of action than ZD-2138.

Related Experiment Videos

  • A single 200 mg oral dose provided significant protection against bronchoconstriction in asthmatics.
  • The drug exhibits excellent oral bioavailability, linear pharmacokinetics, and good tolerability.
  • Pediatric pharmacokinetics mirror adult profiles.

    • Conclusions:

    • ABT-761 is a potent, once-daily 5-lipoxygenase inhibitor with promising efficacy and favorable pharmacokinetics for asthma management.
    • Its improved profile supports its advancement into phase III trials for asthma.